ArticleNature biotechnology2021
Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection.
Article in Nature biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 140 citations in OpenAlex.
- Biophotonics point-of-care diagnostics in low-resource settings: a South African perspective.Journal of biomedical optics · 2026Review
- SARS-CoV-2 Point-of-Care Testing Modalities: Integrating Molecular, Immunological, Biosensor, and AI Approaches.Diagnostics (Basel, Switzerland) · 2026Review
- A broadly applicable split-luciferase biosensor approach for rapid antibody detection in emerging infectious diseases.Applied microbiology and biotechnology · 2026Article
- Optimizing Surface Functionalization for Aptameric Graphene Nanosensors in Undiluted Physiological Media.Sensors (Basel, Switzerland) · 2026Article
- A bioluminescent inhibition immunoassay for detecting GM-CSF inhibitory activity in serum.Clinical and experimental immunology · 2026Article
- Ultrasensitive and long-lasting bioluminescence immunoassay for point-of-care viral antigen detection.Nature biomedical engineering · 2025Article
- Development of a Ready-To-Use Bioluminescence Immunosensor for the One-Step Sensitive Detection of Antibodies Against African Swine Fever Virus.Microbial biotechnology · 2025Article
- A fully automated, ultrasensitive luminescence cascade sensor to address hepatitis C diagnostic disparity.Innovation (Cambridge (Mass.)) · 2025Article
- Rapid and Wash-Free Anti-Drug Antibody Assay Enabled by a Complementary Nanoluciferase Biosensor.Analytical chemistry · 2025Article
- Digital Immunoassay for Rapid Detection of SARS-CoV-2 exposure in a Broad Spectrum of Animals.IEEE sensors journal · 2025Article
- High-throughput multiplexed serology via the mass-spectrometric analysis of isotopically barcoded beads.Nature biomedical engineering · 2025Article
- An immunoassay based on bioluminescent sensors for rapid detection of African swine fever virus antibodies.Journal of clinical microbiology · 2024Article
- Aptameric Metal-Organic Framework Nanobiosensor.ACS applied nano materials · 2024Article
- mRNA Display Pipeline for Protein Biosensor Construction.ACS sensors · 2024Article
- Development of Luminescent Biosensors for Calprotectin.ACS chemical biology · 2024Article
- Quantification of SARS-CoV-2 monoclonal IgG mass fraction by isotope dilution mass spectrometry.Analytical and bioanalytical chemistry · 2024Article
- Mass spectrometry and split luciferase complementation assays reveal the MecA protein interactome ofMicrobiology spectrum · 2024Article
- Recent Advances in Field-Effect Transistor-Based Biosensors for Label-Free Detection of SARS-CoV-2.Small science · 2024Article
- Therapeutic drug monitoring of immunotherapies with novel Affimer-NanoBiT sensor construct.Sensors & diagnostics · 2024Article
- A handheld luminometer with sub-attomole limit of detection for distributed applications in global health.PLOS global public health · 2024Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
19 authors at 3 institutions in 1 country.
Funding
Abstract
Current serology tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies mainly take the form of enzyme-linked immunosorbent assays, chemiluminescent microparticle immunoassays or lateral flow assays, which are either laborious, expensive or lacking sufficient sensitivity and scalability. Here we present the development and validation of a rapid, low-cost, solution-based assay to detect antibodies in serum, plasma, whole blood and to a lesser extent saliva, using rationally designed split luciferase antibody biosensors. This new assay, which generates quantitative results in 30 min, substantially reduces the complexity and improves the scalability of coronavirus disease 2019 (COVID-19) antibody tests. This assay is well-suited for point-of-care, broad population testing, and applications in low-resource settings, for monitoring host humoral responses to vaccination or viral infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.